Innovative Treatment Launches Glaukos has recently launched groundbreaking therapies including Epioxa and iDose TR, targeting both keratoconus and glaucoma management. These innovative products present opportunities for partnerships with healthcare providers and specialty pharmacies to expand adoption and device sales.

Regulatory Advancements The company’s achievement in securing EU MDR certification for iStent infinite and other MIGS therapies indicates a focus on regulatory compliance and international market expansion, opening avenues for global sales growth and cross-border collaborations.

Market Expansion Efforts Participation in prominent industry events like ASCRS 2026 and recent client integrations such as CMS coding support demonstrate Glaukos’s active efforts to increase market visibility and acceptance among clinicians, which can drive sales opportunities through increased demand for their novel ophthalmic solutions.

Patient Support Programs The launch of EpioxaCareConnect signifies Glaukos’s emphasis on patient engagement and comprehensive support systems, providing sales prospects through healthcare providers seeking integrated treatment and patient management solutions to improve therapy adherence.

Financial and Market Position With reported revenues between $100 million and $250 million and recent funding of $30 million, Glaukos is positioned as a growing player in the ophthalmic device sector, suggesting opportunities to target competing clinics and hospitals that are looking to adopt innovative and proven technologies to enhance their service offerings.